Radiotherapy and chemotherapy as therapeutic strategies in extrahepatic biliary duct carcinoma

Strahlentherapie und Onkologie

Volumn 186, Issue 12, 2010, Pages 672-680

  Brunner, Thomas B ^a   Eccles, Cynthia L ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Bile duct cancer; Chemoradiotherapy; Chemotherapy; Radiotherapy; Review

Indexed keywords

ALPHA INTERFERON; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; MITOMYCIN C; OXALIPLATIN;

ADJUVANT THERAPY; ARTICLE; BILE DUCT CARCINOMA; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER RELAPSE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); CONTINUOUS INFUSION; DECOMPRESSION SURGERY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; IMAGE GUIDED RADIOTHERAPY; INTENSITY MODULATED RADIATION THERAPY; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MEDLINE; OVERALL SURVIVAL; PUBLICATION; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); STENT; SURVIVAL TIME; TREATMENT OUTCOME;

AGED; BILE DUCT NEOPLASMS; BILE DUCTS, EXTRAHEPATIC; CHEMOTHERAPY, ADJUVANT; CHOLANGIOCARCINOMA; COMBINED MODALITY THERAPY; HUMANS; LIVER TRANSPLANTATION; NEOADJUVANT THERAPY; PALLIATIVE CARE; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, ADJUVANT; RADIOTHERAPY, INTENSITY-MODULATED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEER PROGRAM; STENTS; SURVIVAL ANALYSIS;

EID: 79951674216     PISSN: 01797158     EISSN: 1439099X     Source Type: Journal    
DOI: 10.1007/s00066-010-2161-y     Document Type: Article

References (72)

1. Alden ME, Mohiuddin M. The impact of radiation dose in combined external beam and intraluminal Ir-192 brachytherapy for bile duct cancer. Int J Radiat Oncol Biol Phys 1994;28:945-51. (Pubitemid 24099877)
2. Andre T, Tournigand C, Rosmorduc O, et al.. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol 2004;15:1339-1343. (Pubitemid 39295020)
3. Ash D. Bile Duct Tumours. In: The GEC ESTRO handobook of brachytherapy (first ed.). Gerbaulet A, Peter R, Mazeron J-J, Meertens H. van Limbergen E, eds. Brussels: The Europeans Society for Therapeutic Radiology and Oncology, 2002, pp 539-42.
4. Bowling TE, Galbraith SM, Hatfield AR, et al. A retrospective comparison of endoscopic stenting alone with stenting and radiotherapy in non-resectable cholangiocarcinoma. Gut 1996;39:852-5. (Pubitemid 27049089)
5. Brunner TB, Schwab D, Meyer T, Sauer R. Chemoradiation May Prolong Survival of Patients with Non-Bulky Unresectable Extrahepatic Biliary CarcinomaA Retrospective Analysis. Strahlenther Onkol 2004;180:751-7. (Pubitemid 40100823)
6. Buskirk SJ, Gunderson LL, Schild SE, et al. Analysis of failure after curative irradiation of extrahepatic bile duct carcinoma. Ann Surg 1992;215: 125-31.
7. Cameron JL, Pitt HA, Zinner MJ, et al. Management of proximal cholangiocarcinomas by surgical resection and radiotherapy. Am J Surg 1990;159:91-7; discussion 97-8.
8. Cantore M, Mambrini A, Fiorentini G, et al. Phase II study of hepatic intraarterial epirubicin and cisplatin, with systemic 5-fluorouracil in patients with unresectable biliary tract tumors. Cancer 2005;103:1402-7. (Pubitemid 40410735)
9. Choi CW, Choi IK, Seo JH, et al. Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas. Am J Clin Oncol 2000;23:425-8. (Pubitemid 32429160)
10. Crane CH, Macdonald KO, Vauthey JN, et al. Limitations of conventional doses of chemoradiation for unresectable biliary cancer. Int J Radiat Oncol Biol Phys 2002;53:969-74. (Pubitemid 34722643)
11. Davids PH, Groen AK, Rauws EA, et al. Randomised trial of self-expanding metal stents versus polyethylene stents for distal malignant biliary obstruction. Lancet 1992;340:1488-92.
12. Dawson LA, Eccles C, Craig T. Individualized image guided iso-NTCP based liver cancer SBRT. Acta Oncol (Stockholm, Sweden) 2006;45:856-64. (Pubitemid 44423132)
13. Dawson LA, McGinn CJ, Normolle D, et al. Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J Clin Oncol 2000;18:2210-8. (Pubitemid 30350212)
14. Dawson LA, Normolle D, Balter JM, et al. Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys 2002;53:810-21. (Pubitemid 34722625)
15. Dawson LA, Sharpe MB. Image-guided radiotherapy: rationale, benefits, and limitations. Lancet Oncol 2006;7:848-58. (Pubitemid 44464078)
16. Deodato F, Clemente G, Mattiucci GC, et al. Chemoradiation and brachytherapy in biliary tract carcinoma: long-term results. Int J Radiat Oncol Biol Phys 2006;64:483-8. (Pubitemid 43083436)
17. Ducreux M, Rougier P, Fandi A, et al. Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin. Ann Oncol 1998;9:653-6. (Pubitemid 28318199)
18. Eccles CL, Bissonnette JP, Craig T, et al. Treatment planning study to determine potential benefit of intensity-modulated radiotherapy versus conformal radiotherapy for unresectable hepatic malignancies. Int J Radiat Oncol Biol Phys 2008;72:582-8.
19. Fields JN, Emami B. Carcinoma of the extrahepatic biliary system-results of primary and adjuvant radiotherapy. Int J Radiat Oncol Biol Phys 1987;13: 331-8. (Pubitemid 17053945)
20. Figueras J, Llado L, Valls C, et al. Changing strategies in diagnosis and management of hilar cholangiocarcinoma. Liver Transpl 2000;6:786-94.
21. Foo ML, Gunderson LL, Bender CE, Buskirk SJ. External radiation therapy and transcatheter iridium in the treatment of extrahepatic bile duct carcinoma. Int J Radiat Oncol Biol Phys 1997;39:929-35. (Pubitemid 27486082)
22. Fritz P, Brambs HJ, Schraube P, et al. Combined external beam radiotherapy and intraluminal high dose rate brachytherapy on bile duct carcinomas. Int J Radiat Oncol Biol Phys 1994;29:855-61. (Pubitemid 24241328)
23. Fuller CD, Dang ND, Wang SJ, et al. Image-guided intensity-modulated radiotherapy (IG-IMRT) for biliary adenocarcinomas: Initial clinical results. Radiother Oncol 2009;92:249-54.
24. Fuller CD, Wang SJ, Choi M, et al. Multimodality therapy for locoregional extrahepatic cholangiocarcinoma: a population-based analysis. Cancer 2009;115:5175-83.
25. Fumex F, Coumaros D, Napoleon B, et al. Similar performance but higher cholecystitis rate with covered biliary stents: results from a prospective multicenter evaluation. Endoscopy 2006;38:787-92. (Pubitemid 44314632)
26. Gerhards MF, van Gulik TM, Gonzalez Gonzalez D, et al. Results of postoperative radiotherapy for resectable hilar cholangiocarcinoma. World J Surg 2003;27:173-9. (Pubitemid 36920167)
27. Glimelius B, Hoffman K, Sjoden PO, et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996;7:593-600. (Pubitemid 26285639)
28. Grove MK, Hermann RE, Vogt DP, aBroughan TA. Role of radiation after operative palliation in cancer of the proximal bile ducts. Am J Surg 1991;161:454-8.
29. Heimbach JK, Gores GJ, Haddock MG, et al. Liver transplantation for unresectable perihilar cholangiocarcinoma. Semin Liver Dis 2004;24:201-7. (Pubitemid 38738348)
30. Hermesse J, Biver S, Jansen N, et al. A dosimetric selectivity intercomparison of HDR brachytherapy, IMRT and helical tomotherapy in prostate cancer radiotherapy. Strahlenther Onkol 2009;185:736-42.
31. Hughes MA, Frassica DA, Yeo CJ, et al. Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct. Int J Radiat Oncol Biol Phys 2007;68:178-82. (Pubitemid 46589827)
32. Ishii H, Furuse J, Nagase M, et al. Relief of jaundice by external beam radiotherapy and intraluminal brachytherapy in patients with extrahepatic cholangiocarcinoma: results without stenting. Hepatogastroenterology 2004;51:954-7. (Pubitemid 38822446)
33. Iwasaki Y, Todoroki T, Fukao K, et al. The role of intraoperative radiation therapy in the treatment of bile duct cancer. World J Surg 1988;12:91-8. (Pubitemid 18074510)
34. Jarnagin WR, Ruo L, Little SA, et al. Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer 2003;98:1689-700. (Pubitemid 37238626)
35. Kaassis M, Boyer J, Dumas R, et al. Plastic or metal stents for malignant stricture of the common bile duct? Results of a randomized prospective study. Gastrointest Endosc 2003;57:178-82. (Pubitemid 36236755)
36. Kaiser GM, Fruhauf NR, Lang H, et al. Impact of intraoperative radiotherapy (IORT) on survival of patients with unresectable hilar cholangiocarcinoma. Hepatogastroenterology 2008;55:1951-4.
37. Kim S, Kim SW, Bang YJ, et al. Role of postoperative radiotherapy in the management of extrahepatic bile duct cancer. Int J Radiat Oncol Biol Phys 2002;54:414-9. (Pubitemid 35286806)
38. Kopek N, Holt MI, Hansen AT, Hoyer M. Stereotactic body radiotherapy for unresectable cholangiocarcinoma. Radiother Oncol 2010;94:47-52.
39. Kopelson G, Harisiadis L, Tretter P, Chang CH. The role of radiation therapy in cancer of the extra-hepatic biliary system: an analysis of thirteen patients and a review of the literature of the effectiveness of surgery, chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys 1977;2:883-94. (Pubitemid 8253094)
40. Kuvshinoff BW, Armstrong JG, Fong Y, et al. Palliation of irresectable hilar cholangiocarcinoma with biliary drainage and radiotherapy. Br J Surg 1995;82:1522-5.
41. Lu JJ, Bains YS, Abdel-Wahab M, et al. High-dose-rate remote afterloading intracavitary brachytherapy for the treatment of extrahepatic biliary duct carcinoma. Cancer J (Sudbury, Mass) 2002;8:74-8.
42. McMasters KM, Tuttle TM, Leach SD, et al. Neoadjuvant chemoradiation for extrahepatic cholangiocarcinoma. Am J Surg 1997;174:605-8; discussion 608-9.
43. Nairz O, Merz F, Deutschmann H, et al A strategy for the use of image-guided radiotherapy (IGRT) on linear accelerators and its impact on treatment margins for prostate cancer patients. Strahlenther Onkol 2008;184:663-7.
44. Nehls O, Klump B, Arkenau HT, et al. Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial. Br J Cancer 2002;87:702-4. (Pubitemid 35178744)
45. Nelson JW, Ghafoori AP, Willett CG, et al. Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys 2009;73:148-53.
46. Niemierko A. Reporting and analyzing dose distributions: a concept of equivalent uniform dose. Med Phys 1997;24:103-10. (Pubitemid 27051935)
47. Norkus D, Miller A, Kurtinaitis J, et al. A randomized trial comparing hypofractionated and conventionally fractionated three-dimensional externalbeam radiotherapy for localized prostate adenocarcinoma : a report on acute toxicity. Strahlenther Onkol 2009;185:715-21.
48. Ohnishi H, Asada M, Shichijo Y, et al. External radiotherapy for biliary decompression of hilar cholangiocarcinoma. Hepatogastroenterology 1995;42:265-8.
49. Park do H, Kim MH, Choi JS, et al. Covered versus uncovered wallstent for malignant extrahepatic biliary obstruction: a cohort comparative analysis. Clin Gastroenterol Hepatol. 2006, 4:790-6. (Pubitemid 43825819)
50. Park SW, Park YS, Chung JB, et al. Patterns and relevant factors of tumor recurrence for extrahepatic bile duct carcinoma after radical resection. Hepatogastroenterology 2004;51:1612-8. (Pubitemid 39389743)
51. Patt YZ, Jones DV, Jr., Hoque A, et al. Phase II trial of intravenous flourouracil and subcutaneous interferon alfa-2b for biliary tract cancer. J Clin Oncol 1996;14:2311-5. (Pubitemid 26264882)
52. Penz M, Kornek GV, Raderer M, et al. Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. Ann Oncol 2001;12: 183-6. (Pubitemid 32223865)
53. Pitt HA, Nakeeb A, Abrams RA, et al. Perihilar cholangiocarcinoma. Postoperative radiotherapy does not improve survival. Ann Surg 1995;221: 788-97; discussion 797-8.
54. Robertson JM, McGinn CJ, Walker S, et al. A phase I trial of hepatic arterial bromodeoxyuridine and conformal radiation therapy for patients with primary hepatobiliary cancers or colorectal liver metastases. Int J Radiat Oncol Biol Phys 1997;39:1087-92. (Pubitemid 27506161)
55. Schoenthaler R, Phillips TL, Castro J, et al. Carcinoma of the extrahepatic bile ducts. The University of California at San Francisco experience. Ann Surg 1994;219:267-74.
56. Serafini FM, Sachs D, Bloomston M, et al. Location, not staging, of cholangiocarcinoma determines the role for adjuvant chemoradiation therapy. Am Surg 2001;67:839-43; discussion 843-4. (Pubitemid 33738900)
57. Shinohara ET, Mitra N, Guo M, Metz JM. Radiation therapy is associated with improved survival in the adjuvant and definitive treatment of intrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys 2008;72:1495-501.
58. Shinohara ET, Mitra N, Guo M, Metz JM. Radiotherapy is associated with improved survival in adjuvant and palliative treatment of extrahepatic cholangiocarcinomas. Int J Radiat Oncol Biol Phys 2009;74:1191-8.
59. Soderlund C, Linder S. Covered metal versus plastic stents for malignant common bile duct stenosis: a prospective, randomized, controlled trial. Gastrointest Endosc 2006;63:986-95. (Pubitemid 43776145)
60. Sterzing F, Schubert K, Sroka-Perez G, et al. Helical tomotherapy. Experiences of the first 150 patients in Heidelberg. Strahlenther Onkol 2008;184: 8-14.
61. Takada T, Amano H, Yasuda H, et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 2002;95:1685-95.
62. Takamura A, Saito H, Kamada T, et al. Intraluminal low-dose-rate 192Ir brachytherapy combined with external beam radiotherapy and biliary stenting for unresectable extrahepatic bile duct carcinoma. Int J Radiat Oncol Biol Phys 2003;57:1357-65. (Pubitemid 37443977)
63. Takeda Y, Hasuike Y, Kashiwazaki M, Tsujinaka T. Adjuvant arterial infusion chemotherapy for patients with biliary cancer. Gan to kagaku ryoho 2004;31:1835-7.
64. Thomas E, Chapet O, Kessler ML, et al. Benefit of using biologic parameters (EUD and NTCP) in IMRT optimization for treatment of intrahepatic tumors. Int J Radiat Oncol Biol Phys 2005;62:571-8. (Pubitemid 40704477)
65. Thongprasert S. The role of chemotherapy in cholangiocarcinoma. Ann Oncol 2005;16(Suppl 2):ii93-6. (Pubitemid 40908942)
66. Todoroki T, Ohara K, Kawamoto T, et al. Benefits of adjuvant radiotherapy after radical resection of locally advanced main hepatic duct carcinoma. Int J Radiat Oncol Biol Phys 2000;46:581-7. (Pubitemid 30100635)
67. Tse RV, Hawkins M, Lockwood G, et al. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 2008;26:657-64. (Pubitemid 351264363)
68. Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. New Engl J Med 2010;362:1273-81.
69. Vallis KA, Benjamin IS, Munro AJ,et al. External beam and intraluminal radiotherapy for locally advanced bile duct cancer: role and tolerability. Radiother Oncol 1996;41:61-6. (Pubitemid 26396298)
70. Veeze-Kuijpers B, Meerwaldt JH, Lameris JS, et al. The role of radiotherapy in the treatment of bile duct carcinoma. Int J Radiat Oncol Biol Phys 1990;18:63-7. (Pubitemid 20047392)
71. Wharton JT, Delclos L, Gallager S, Smith JP. Radiation hepatitis induced by abdominal irradiation with the cobalt 60 moving strip technique. Am J Roentgenol Radium Ther Nucl Med 1973;117:73-80.
72. Xu ZY, Liang SX, Zhu J, et al. Prediction of radiation-induced liver disease by Lyman normal-tissue complication probability model in three-dimensional conformal radiation therapy for primary liver carcinoma. Int J Radiat Oncol Biol Phys 2006;65:189-95.